For fifteen years, biotech has treated lentiviral vector manufacturing like a solved utility: identify a supplier, contract for production, move on. That model broke when CAR-T and advanced cell therapies required point-of-care manufacturing, creating demand for affordable, scalable lentiviral vector supply to enable distributed production. Vector BioMed was founded by members of the team behind Kymriah®, the first FDA-approved CAR-T therapy, and brings direct experience translating advanced therapies into scalable, manufacturable solutions.
The bottleneck is not discovery. CAR-T, TCR-engineered T cells, allogeneic cell therapies, and in vivo gene applications all exist. The bottleneck is what happens before they reach a patient: vector supply, process optimisation, scalability, cost, and regulatory readiness all compound at once.
When vector supply is constrained or expensive, it stalls development before clinical efficacy ever gets tested. When cell therapy production requires high-complexity centralised manufacturing, only a handful of geographical locations can deliver therapy to patients. When cost is baked into the supply chain, treatments price themselves out of reach even where infrastructure exists. These are not procurement problems. They are strategy problems. They determine which programmes survive to clinic and which don’t.
“Manufacturing is the partner you choose, not the problem you solve. That choice determines success faster than any other factor except clinical outcome.” system. This level of biological relevance helps reduce development risk long before a programme reaches the clinic.”
– Dr. Michael Kadan, Chief Operating Officer, Vector BioMed
Vector BioMed’s response is to unbind those three variables: provide low-cost lentiviral vector supply to reduce the cost barrier to cell therapy manufacturing, design portable cell manufacturing processes that work at academic medical centres, regional hubs, and point-of-care settings, and build the supply chain infrastructure that makes distributed production viable.
The LENTIVERSE™ platform offers two paths. VectorCraft supports bespoke vector development for programmes with specific biology requirements, paired with a manufacturing partner that scales with the developer’s clinical and regulatory demands. LaunchSuite provides ready-to-deploy lentiviral vector solutions for common CAR-T targets (CD19, BCMA) alongside established manufacturing workflows, reducing the engineering burden and compressing the path to clinical material.
Together, this platform answers a question biotech developers now must ask themselves: should manufacturing excellence be a core capability we build or a strategic partnership we choose? The old answer was “build.” The new answer is increasingly “partner,” because the engineering challenges of lentiviral vector production are sufficiently specialised and that means outsourcing will often beat in-house.
A developer selecting a manufacturing partner can no longer think therapy-by-therapy. They need a partner that can scale across therapeutic areas as their pipeline expands. What distinguishes Vector BioMed’s approach is the breadth of manufacturing flexibility. The platform was engineered to support both ex vivo applications (cell engineering, such as CAR-T) and in vivo applications (direct patient administration in gene therapy).
More importantly, this approach answers a geography question. When Vector BioMed works with healthcare systems in lower-income settings (through partnerships like Caring Cross and Fiocruz in Brazil), demonstrating that CAR-T can be manufactured and delivered locally at approximately $35,000 per dose instead of $350,000 to $400,000, the calculus shifts. Access is no longer a function of proximity to an elite academic centre. Infrastructure becomes portable. Scale becomes possible without centralisation.
“Infrastructure becomes portable. Scale becomes possible without centralisation”
– Dr. Boro Dropulić, Chief Executive Officer, Vector BioMed
That fundamentally reframes how biotech developers think about manufacturing strategy. It goes from “where is the CDMO with spare capacity” to “what manufacturing model gives my therapy the reach my market demands”. For cell and gene therapies serving large or geographically distributed patient populations, that is a different question with a different answer.
Vector BioMed currently supports over 40 clients across 11 countries from a 30,000-square-foot facility in Gaithersburg, with CGMP cleanroom capacity designed for concurrent multi-product manufacturing. The firm’s track record includes a growing number of CGMP batches and vector titres consistently exceeding 10^9 TU/mL. But the numbers are secondary to the fact that specialised lentiviral vector manufacturing is no longer a rare capability requiring years of partnership negotiation and millions in upfront investment (in several cases, with strings attached). It has become a transparent service layer that biotechs can plug into early, stay with as programmes evolve, and leverage for a pragmatic commercialization strategy.
For developers working across the biotech landscape, in diverse therapeutic areas, rare indications, and novel targets, this is a material shift in how development strategy is built. Manufacturing is no longer a problem to solve; it’s a strategic choice of the right partner. And that choice, increasingly, determines success faster than any other single factor except clinical outcome itself.
Vector BioMed’s philosophy, expressed in the framing “all paths leading to cure,” is that access and manufacturing are one challenge, not two. Price discounts are not the way to lower the cost of therapy. Lower cost is achieved by removing friction from the entire system: simplifying workflows, engineering new efficiencies, distributing capacity, avoiding unnecessary centralisation, and building infrastructure that can travel. That is a biotech imperative, not a vendor feature. And it is fast becoming non-negotiable for developers serious about patient reach, not just patient efficacy.
“You lower cost by removing friction from the entire system: simplifying workflows, distributing capacity, avoiding unnecessary centralization, building infrastructure that can travel.”
– Dr. Boro Dropulić, Chief Executive Officer, Vector BioMed
